Retaane® in Age-Related Macular Degeneration
The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options.
While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available.
Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.
|Age Related Macular Degeneration||Drug: juxtascleral depot injection of Retaane||Phase 2 Phase 3|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Retaane® in Age-Related Macular Degeneration|
- Increase in VA [ Time Frame: 6 months ]
- Decrease in Macula Edema [ Time Frame: 6 months ]
|Study Start Date:||February 2006|
|Study Completion Date:||March 2007|
Patients treated with Retaane
Drug: juxtascleral depot injection of Retaane
juxtascleral depot injection of Retaane
Please refer to this study by its ClinicalTrials.gov identifier: NCT00569569
|Study Chair:||Susanne Binder, M.D.||no affiliation|